Atopic Dermatitis
Conditions
Interventions
Trial group:Ivarmacitinib Sulfate Tablets orally at 4 mg once daily for a duration of 12 weeks.
Sponsors
The People’s Hospital of Dehong Prefecture
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Adults with moderate to severe AD who meet Williams' diagnostic criteria, have an IGA score of >=3, an EASI score of >=7.1, an SCORAD score of >=25, a PP-NRS score of >=4, a body surface affected area of >=10%, and a disease course of more than 6 months
Exclusion criteria
Exclusion criteria: 1.Previous treatment with JAK inhibitors; 2.Hematologic abnormalities: granulocytopenia (absolute neutrophil count <1.0×10^9/L), lymphocytopenia (absolute lymphocyte count <0.5×10^9/L), anemia (hemoglobin <80 g/L); 3.Active hepatitis B or active tuberculosis; 4.Severe bacterial or fungal infections; 5.Pregnancy or lactation; 6.Dysfunction of substantial organs such as the liver, kidneys, or heart; 7.Current diagnosis of malignancy; 8.Presence of psychiatric disorders or lack of capacity or limited capacity to consent; 9.Refusal to sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Epidermal thickness;Keratin 1;Keratin 5;Keratin 10;Keratin 14;Filaggrin;Loricrin;Involucrin;Desmoglein 1;Desmocollin 1;Interleukin 4;Interleukin 5;Interleukin 13;Interleukin 25;Interleukin 31;Interleukin 33;Low-Density Lipoprotein Cholesterol;High-Density Lipoprotein Cholesterol;Total Cholesterol;Triglycerides;Total IgE;Investigator’s Global Assessment Score Scale;Eczema Area and Severity Index Score Scale;Peak Pruritus Numerical Rating Scale;Scoring Atopic Dermatitis Index Score Scale;Dermatology Life Quality Index/Children Dermatology Life Quality Index;Histopathological features; | — |
Countries
China
Contacts
Public ContactJiang Xin
The People’s Hospital of Dehong Prefecture
Outcome results
None listed